Factors predictive of remission at three years
| Baseline variable | p Value* | OR (95% CI)* |
|---|---|---|
| *Significance level calculated using the χ2 with Yates’ correction. | ||
| †DRB1*04 includes *0401, 0404, 0405, and 0408. | ||
| Anti-CCP, anti-cyclic citrullinated protein; CI, confidence interval; DAS, disease activity score; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; OR, odds ratio; RF, rheumatoid factor. | ||
| DAS <4 | 0.0009 | 3.2 (1.6 to 6.5) |
| HAQ score <1.25 | 0.0087 | 2.8 (1.3 to 6.4) |
| Ritchie score <17 | 0.019 | 2.29 (1.1 to 4.6) |
| C reactive protein <14.5 mg/l | 0.041 | 2 (1.0 to 4.1) |
| Morning stiffness <60 min | 0.051 | 2.1 (0.98 to 4.8) |
| Total Sharp score <4 | 0.053 | 1.99 (0.98 to 4.0) |
| Anti-HSP90 negativity | 0.057 | 2.6 (0.94 to 7.3) |
| Erosion score = 0 | 0.062 | 1.97 (0.95 to 4) |
| Tender joint count <21 | 0.069 | 2 (0.94 to 4.3) |
| Pain on visual analogue scale <59 mm | 0.085 | 1.94 (0.9 to 4.1) |
| IgA RF negativity | 0.14 | 1.75 (0.8 to 3.8) |
| No extra-articular manifestations | 0.15 | 2.89 (0.6 to 13) |
| Anticalpastatin antibody negativity | 0.18 | 0.54 (0.2 to 1.3) |
| IgM RF negativity | 0.41 | 1.34 (0.65 to 2.8) |
| Swollen joint count <9 | 0.54 | 1.2 (0.6 to 2.5) |
| ESR <28 mm/h | 0.77 | 1.1 (0.56 to 2.1) |
| Antikeratin antibody negativity | 0.82 | 1.08 (0.5 to 2.2) |
| HLA-DRB1*01 negativity | 0.81 | 0.91 (0.4 to 2.3) |
| HLA-DRB1*04 negativity† | 0.88 | 0.95 (0.5 to 1.8) |
| Anti-CCP antibody negativity | 0.95 | 1.02 (0.4 to 2.2) |